Mechanism Summary

Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist analog used in the management of type 2 diabetes mellitus, prevention of cardiovascular complications associated with diabetes, and obesity.

Pathways

References

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
• https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
• +13 more

Notes

Expansion-batch evidence packet requires human review before publication. | RESOLVED 2026-08-29: LEADER trial primary-outcome figure was corrected to HR 0.87 (95% CI 0.78-0.97, p=0.01 for superiority) after independently re-fetching and quoting the primary Marso et al. NEJM 2016 publication (PMC4985288); prior figure (HR 0.82) was a misattributed subgroup statistic. | RESOLVED 2026-08-29: CAS number (204656-20-2, via PubChem), UNII (839I73S42A, via FDA/NCATS GSRS), RxNorm RxCUI (475968, via RxNav), and ChEMBL ID (CHEMBL4084119, via ChEMBL API) were resolved and added to compound.externalIdentifiers this session. | PARTIAL 2026-08-29: for the Victoza/Saxenda approved-indication and boxed-warning claims, independent review this session added a second, materially different source family (Drugs@FDA structured-database records, NDA 022341 and NDA 206321) beyond the live FDA label PDFs already checked, confirming active approval and marketing status. A professional-guideline family (e.g., ADA Standards of Care) has not yet been consulted for these fieldAuthorityRequired claims; remains a documented gap pending further review. | PMID for compound.externalIdentifiers.pmid intentionally left null: no single canonical PMID applies to a compound identity record (liraglutide is associated with many publications, not one defining PMID). | Liraglutide-specific counterfeit/falsified-product incident data remains unconfirmed after an independent 2026-08-29 search across FDA, WHO, and peer-reviewed pharmacovigilance sources; every documented incident found was semaglutide/Ozempic-specific. Claim's class-level framing is accurate and stays review-gated as-is. | Boxed-warning and pancreatitis adverse-effect claims were independently corroborated this session (live FDA labels; Cleveland Clinic Journal of Medicine review) but a professional-guideline or systematic-review cross-check beyond the regulator/label and single-review sources used was not exhaustively pursued; low-risk given source authority tier, documented for completeness. | Compiled draft requires human review before publication.